TetraPhase Pharmaceuticals Outlines Plans for Phase 3 Clinical Trial of Eravacycline IV/Oral in Complicated Urinary Tract Infections

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), today announced the design of its planned Phase 3 IV/oral clinical trial of the Company’s lead antibiotic candidate eravacycline in the treatment of complicated urinary tract infections (cUTI). When initiated, this trial will be the second Phase 3 study of eravacycline underway. Tetraphase enrolled the first patient in a Phase 3 trial of eravacycline IV in complicated intra-abdominal infections (cIAI) in late August. “Eravacycline is the only late-stage antibiotic that is being developed to be dosed intravenously and orally, and that offers broad-spectrum activity, including coverage of carbapenem-resistant bacteria such as E. coli and Klebsiella spp.,” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “As outlined in a recent report from the Centers for Disease Control and Prevention, multi-drug resistant infections, particularly Gram-negative infections, are a serious and rapidly growing threat to public health. With the start of this study, Tetraphase will be evaluating eravacycline in a Phase 3 program in each of two indications, cIAI and cUTI, taking full advantage of an FDA regulatory pathway designed to improve the availability of therapies addressing these serious infections.”

Help employers find you! Check out all the jobs and post your resume.